American Heart Association invests in the future of heart and brain health research

Bios­plice’s os­teoarthri­tis drug has failed a Phase 3 clin­i­cal tri­al, ac­cord­ing to the drug­mak­er, sig­nif­i­cant­ly cloud­ing the drug’s chances of ap­proval and the fu­ture of

FDA advisors told the agency that the current evidence does not support approval of gefapixant for chronic cough, a condition where no approved therapy exists.